Announcing A Compassionate Use Trial of Alpharadin

Radium-223 choride, also known as Alpharadin, has demonstrated a small but statistically significant survival benefit in men with symptomatic metastatic castrate resistant prostate cancer (mCRPC). My expectation is that it will be approved by the FDA some time later this year. Additionally, my hope is that it will also be approved Europe. To read more [...]

REVLIMID FAILS TO EXTEND SURVIVAL IN ADVANCED PROSTATE CANCER

The late-stage trial of Revlimid (lenalidomide) for the treatment of advanced prostate cancer has been discontinued after preliminary data shows that it does not extend survival! The independent monitoring committee recommended that the pivotal Phase III Mainsail trial be halted after it determined that adding Revlimid to standard treatments would not significantly increase the overall [...]

OncoGenex To Present OGX-427 Data At ASCO 2012 Genitourinary Cancers Symposium

Maybe we are about to have another new treatment for advanced prostate cancer that will earn the coveted descriptor, “ON THE HORIZON.” OncoGenex Pharmaceuticals Inc. (OGXI) has said that they will be presenting preliminary data from their phase 2 trials evaluating their investigational compound OGX-427, in prostate and bladder cancer. The data will be presented [...]

The Value of Evaluating Circulating Tumor Cells – Better Survival Predictions

The use of the PSA as a prostate cancer screening tool has been a controversial issue for many years. Within the last year the issue has again come to the forefront of the public awareness, especially because of the recent move of the U.S Preventative Task Force to discourage using the PSA as a screening [...]

Bavarian Nordic Initiates Pivotal Phase 3 Trial of PROSTVAC® Prostate Cancer Immunotherapy

Bavarian Nordic A/S (BAVA) announced on November 15, that its subsidiary, BN ImmunoTherapeutics has started the pivotal Phase 3 trial of PROSTVAC® for men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer. The trial is being conducted under a Special Protocol Assessment agreement with the FDA. Notice this trial has the same criteria as [...]

Go to Top